- Silo Wellness (SILO) is partnering with Oregon-based psilocybin producer, Satya
- The companies plan to develop a robust ecosystem to support the well-being of Oregonian psilocybin patients and entrepreneurs alike
- Pursuant to their two-year agreement, Satya has granted Silo a right of first refusal that guarantees Silo’s affiliates first rights to any of Satya’s psilocybin biomass
- Founder and CEO, Mike Arnold, spoke with Shoran Devi about the news
- Silo Wellness is a growth-oriented holding company focused on psychedelic opportunities
- Silo Wellness (SILO) last traded at $0.015 per share
Silo Wellness (SILO) is partnering with Oregon-based psilocybin producer, Satya.
Satya offers licensed psilocybin products and services with a focus on solving mental-health challenges in Oregon. It announced a Portland-area psilocybin therapy center earlier this year.
The companies plan to develop a robust ecosystem to support the well-being of Oregonian psilocybin patients and entrepreneurs alike. Toward this end, they have established a raw materials supply and purchase agreement, including a right of first refusal (ROFR) that guarantees Silo’s affiliates first rights to any of Satya’s psilocybin biomass.
Under the agreement, Satya will provide 10 mg analyte psilocybin doses and 1 mg analyte psilocybin microdoses to any Silo affiliate properly licensed under Ballot Measure 109.
The buyer shall pay $50,000 in advance for the materials, which shall be credited against future purchases.
The agreement is for an initial two years terminating March 30, 2025, with a renewal for successive one-year periods.
Founder and CEO, Mike Arnold, spoke with Shoran Devi about the news.
Silo Wellness is a growth-oriented holding company focused on psychedelic opportunities. The company was founded in 2018 in Oregon and is headquartered in Toronto with a presence in Jamaica.
Silo Wellness (SILO) last traded at $0.015 per share.
This is sponsored content, please see full disclaimer here.
